Log in
NASDAQ:UMRX

Unum Therapeutics Stock Forecast, Price & News

$2.74
-0.11 (-3.86 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.50
Now: $2.74
$2.94
50-Day Range
$2.16
MA: $2.64
$3.05
52-Week Range
$0.29
Now: $2.74
$3.72
Volume518,771 shs
Average Volume1.27 million shs
Market Capitalization$104.84 million
P/E RatioN/A
Dividend YieldN/A
Beta3.93
Unum Therapeutics Inc., a biopharmaceutical company, develops and commercializes immunotherapy products for cancer. The company is developing ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets glypican-3 that improve T cell functionality in the solid tumor microenvironment. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Unum Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.91 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UMRX
CUSIPN/A
Phone617-945-5576

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.50 million
Book Value$1.04 per share

Profitability

Net Income$-31,830,000.00

Miscellaneous

Employees72
Market Cap$104.84 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$2.74
-0.11 (-3.86 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Unum Therapeutics (NASDAQ:UMRX) Frequently Asked Questions

How has Unum Therapeutics' stock price been impacted by Coronavirus?

Unum Therapeutics' stock was trading at $0.3736 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, UMRX shares have increased by 633.4% and is now trading at $2.74.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Unum Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unum Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Unum Therapeutics
.

When is Unum Therapeutics' next earnings date?

Unum Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Unum Therapeutics
.

How were Unum Therapeutics' earnings last quarter?

Unum Therapeutics Inc (NASDAQ:UMRX) released its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.03. The company earned $0.53 million during the quarter. Unum Therapeutics had a negative net margin of 96.84% and a negative return on equity of 87.78%.
View Unum Therapeutics' earnings history
.

What price target have analysts set for UMRX?

3 brokerages have issued 1-year target prices for Unum Therapeutics' shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate Unum Therapeutics' stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 33.8% from the stock's current price.
View analysts' price targets for Unum Therapeutics
.

Are investors shorting Unum Therapeutics?

Unum Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 988,400 shares, an increase of 32.2% from the August 15th total of 747,700 shares. Based on an average daily trading volume, of 2,780,000 shares, the short-interest ratio is presently 0.4 days. Approximately 6.4% of the company's shares are short sold.
View Unum Therapeutics' Short Interest
.

Who are some of Unum Therapeutics' key competitors?

What other stocks do shareholders of Unum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unum Therapeutics investors own include Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Pennsylvania R.E.I.T. (PEI), Cannabics Pharmaceuticals (CNBX), BioNano Genomics (BNGO), KushCo (KSHB), Novan (NOVN), AEterna Zentaris (AEZS) and Zosano Pharma (ZSAN).

Who are Unum Therapeutics' key executives?

Unum Therapeutics' management team includes the following people:
  • Dr. Charles Wilson, CEO, Pres & Director (Age 55, Pay $807.42k)
  • Mr. Matthew S. Osborne, Chief Financial Officer (Age 48, Pay $517.98k)
  • Dr. Dario Campana, Scientific Founder & Chair of Scientific Advisory Board
  • Mr. John L. Green C.A., C.P.A., Principal Accounting Officer (Age 40)
  • Mr. Larry Weiner, VP of Technical Operations

When did Unum Therapeutics IPO?

(UMRX) raised $75 million in an IPO on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

What is Unum Therapeutics' stock symbol?

Unum Therapeutics trades on the NASDAQ under the ticker symbol "UMRX."

Who are Unum Therapeutics' major shareholders?

Unum Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FIL Ltd (2.18%) and Bridgeway Capital Management Inc. (0.50%). Company insiders that own Unum Therapeutics stock include Seth Ettenberg and Venrock Healthcare Capital Par.
View institutional ownership trends for Unum Therapeutics
.

Which major investors are selling Unum Therapeutics stock?

UMRX stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd.
View insider buying and selling activity for Unum Therapeutics
.

Which major investors are buying Unum Therapeutics stock?

UMRX stock was acquired by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc..
View insider buying and selling activity for Unum Therapeutics
.

How do I buy shares of Unum Therapeutics?

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unum Therapeutics' stock price today?

One share of UMRX stock can currently be purchased for approximately $2.74.

How big of a company is Unum Therapeutics?

Unum Therapeutics has a market capitalization of $104.84 million and generates $22.50 million in revenue each year. The company earns $-31,830,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Unum Therapeutics employs 72 workers across the globe.

What is Unum Therapeutics' official website?

The official website for Unum Therapeutics is www.unumrx.com.

How can I contact Unum Therapeutics?

Unum Therapeutics' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-945-5576 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.